ArticleFrontiers in neurology2012
Efficacy of zolpidem for dystonia: a study among different subtypes.
Article in Frontiers in neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Zolpidem for the Treatment of Dystonia.Frontiers in neurology · 2019Pooled it
- Sleep-Related Eating Disorder and Sexsomnia; Two Rare Parasomnias? A Mini-Review with Illustrative Case-Reports.International journal of sexual health : official journal of the World Association for Sexual Health · 2025Article
- Efficacy and Safety of Zolpidem for Musician's Dystonia.Journal of movement disorders · 2024Article
- Cell-specific Dyt1 ∆GAG knock-in to basal ganglia and cerebellum reveal differential effects on motor behavior and sensorimotor network function.Experimental neurology · 2023Article
- Dystonias: Clinical Recognition and the Role of Additional Diagnostic Testing.Seminars in neurology · 2023Article
- Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study.Frontiers in neurology · 2022Article
- Two Cases of Monozygotic Twins with Early-onset Isolated (DYT1) Dystonia Effectively Treated with Bilateral Globus Pallidus Internus Stimulation.NMC case report journal · 2022Article
- Patient selection and injection techniques for botulinum neurotoxin in oromandibular dystonia.Clinical parkinsonism & related disorders · 2022Review
- Dystonia and leveraging oral pharmacotherapy.Journal of neural transmission (Vienna, Austria : 1996) · 2021Review
- Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update.Frontiers in neurology · 2021Review
- Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Treatment of dystonia and tics.Clinical parkinsonism & related disorders · 2020Review
- Clinical Management of Dystonia in Childhood.Paediatric drugs · 2017Review
- Dystonic Dysarthria in Wilson Disease: Efficacy of Zolpidem.Frontiers in neurology · 2017Article
- A Case Report of Psychoactive Drugs Aggravating and Alleviating Meige Syndrome.Shanghai archives of psychiatry · 2016Article
- Medical treatment of dystonia.Journal of clinical movement disorders · 2016Review
- Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.Parkinson's disease · 2016Review
- Update on treatments for dystonia.Current neurology and neuroscience reports · 2014Review
- Treatment of dystonia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Poststroke Choreodystonia Responsive to Zopiclone: Further Evidence of a Role for the "Z-Drugs" in Hyperkinetic Movement Disorders.Movement disorders clinical practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although there are some newly developed options to treat dystonia, its medical treatment is not always satisfactory. Zolpidem, an imidazopyridine agonist with a high affinity on benzodiazepine subtype receptor BZ1 (ω1), was found to improve clinical symptoms of dystonia in a limited number of case reports. To investigate what subtype of dystonia is responsive to the therapy, we conducted an open label study to assess the efficacy of zolpidem (5-20 mg) in 34 patients suffering from miscellaneous types of dystonia using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). Patients were entered into the study if they had been refractory to other medications as evaluated by BFMDRS (no change in the previous two successive visits). After zolpidem therapy, the scores in the patients as a whole were decreased from 7.2 ± 7.9 to 5.5 ± 5.0 (P = 0.042). Patients with generalized dystonia, Meige syndrome/blepharospasm, and hand dystonia improved in the scale by 27.8, 17.8, and 31.0%, respectively, whereas no improvement was found in cervical dystonia patients. Overall response rate among patients were comparable to that of trihexyphenidyl. Zolpidem may be a therapeutic option for generalized dystonia, Meige syndrome, and hand dystonia including musician's. Drowsiness was the dose-limiting factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.